The latest price target for Tenet Healthcare (NYSE:THC) was reported by Guggenheim on March 12, 2026. The analyst firm set a price target for $283.00 expecting THC to rise to within 12 months (a possible 47.50% upside). 53 analyst firms have reported ratings in the last year.

The latest analyst rating for Tenet Healthcare (NYSE:THC) was provided by Guggenheim, and Tenet Healthcare maintained their buy rating.

The last upgrade for Tenet Healthcare Corp happened on May 29, 2025 when Wells Fargo raised their price target to $195. Wells Fargo previously had an equal-weight for Tenet Healthcare Corp.

The last downgrade for Tenet Healthcare Corp happened on July 28, 2025 when Wolfe Research changed their price target from N/A to N/A for Tenet Healthcare Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tenet Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tenet Healthcare was filed on March 12, 2026 so you should expect the next rating to be made available sometime around March 12, 2027.

While ratings are subjective and will change, the latest Tenet Healthcare (THC) rating was a maintained with a price target of $271.00 to $283.00. The current price Tenet Healthcare (THC) is trading at is $191.86, which is out of the analyst’s predicted range.